Research programme: ADAPTIR mono-specific therapeutics - Aptevo Therapeutics

Drug Profile

Research programme: ADAPTIR mono-specific therapeutics - Aptevo Therapeutics

Alternative Names: A2M1; ADAPTIR™ mono-specific therapeutics; AH65; anti-CD20 SMIP; DRACO; DRACO anti-CD3 SMIP; ES 301; SMIP - Emergent BioSolutions; SMIPs - Emergent/Pfizer; X1 - Emergent BioSolutions

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Trubion Pharmaceuticals
  • Developer Aptevo Therapeutics
  • Class Antibodies; Peptides; Protein diagnostics
  • Mechanism of Action CD20 antigen modulators; CD3 antigen inhibitors; Immunosuppressants; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
  • 31 Mar 2017 Candidates from this research programme are available for licensing as of 31 Mar 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top